Non Hodgkin Lymphoma News and Research

RSS

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine.

18 Feb 2021

$FDA approves cell-based gene therapy to treat adults with relapsed or refractory large-B-cell lymphoma$

FDA approves cell-based gene therapy to treat adults with relapsed or refractory large-B-cell lymphoma

Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.

5 Feb 2021

Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients

Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

2 Feb 2021

ADC histogram analysis can predict tumor proliferation, survival in immunocompetent patients with PCNSL

The cover for issue 45 of Oncotarget features Figure 3, "Representative images of whole tumor volume segmentation of the co-registered T1 post-contrast sequence and apparent diffusion coefficient (ADC) map, yielding the corresponding ADC histogram distribution utilized for data analysis," recently published in "Diffusion-weighted MR imaging histogram analysis in HIV positive and negative patients with primary central nervous system lymphoma as a predictor of outcome and tumor proliferation" by Khan, et al.

12 Jan 2021

NCCN publishes new informational resources on health and wellness for cancer survivors

Today, the National Comprehensive Cancer Network announced the publication of new, free informational resources on health and wellness for cancer survivors.

5 Jan 2021

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Roswell Park Comprehensive Cancer Center's Francisco J. Hernandez-Ilizaliturri, MD, along with a team of researchers from other institutions, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

7 Dec 2020

Testing for tumor DNA can help predict risk of relapse after transplant in DLBCL patients

Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse.

7 Dec 2020

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial.

6 Dec 2020

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.

1 Dec 2020

Study finds increasing incidence of cancer among adolescents and young adults

Cancer cases in adolescents and young adults have risen by 30% during the last four decades, with kidney cancer rising at the greatest rate, according to researchers at Penn State College of Medicine.

1 Dec 2020

Radiation therapy before CART-BCMA appears to be a safe option for multiple myeloma patients

Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy, according to a new study from researchers in the Abramson Cancer Center at the University of Pennsylvania to be presented Tuesday, October 27, at the virtual American Society for Radiation Oncology Annual Meeting (Abstract #35562).

27 Oct 2020

Study uses a statistical approach to reveal patterns of cancer incidence

QUT researchers have used nationwide cancer mapping statistics to develop a new mathematical model so health professionals can further question patterns relating to the disease.

13 Aug 2020

Scientists identify genetic link to predict treatment response in patients with aggressive blood cancer

A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.

13 Aug 2020

FDA approves first CAR T-cell therapy for patients with mantle cell lymphoma

The U.S. Food and Drug Administration granted accelerated approval for brexucabtagene autoleucel (TECARTUS™, formerly KTE-X19) as the first and only CAR T-cell therapy for patients with mantle cell lymphoma (MCL) relapsed or refractory to prior treatments.

28 Jul 2020

AI Therapeutics announces start of Phase II clinical trial of potential COVID-19 treatment

AI Therapeutics announced the start of Phase II clinical trial for the treatment of newly diagnosed COVID-19 patients in collaboration with Yale University.

27 Jul 2020

First CAR T-cell therapy for mantle cell lymphoma receives FDA approval

Today's Food and Drug Administration approval of the first CAR T-cell therapy for mantle cell lymphoma represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy.

24 Jul 2020

Non Hodgkin Lymphoma News and Research

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

FDA approves cell-based gene therapy to treat adults with relapsed or refractory large-B-cell lymphoma

Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients

ADC histogram analysis can predict tumor proliferation, survival in immunocompetent patients with PCNSL

NCCN publishes new informational resources on health and wellness for cancer survivors

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Testing for tumor DNA can help predict risk of relapse after transplant in DLBCL patients

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Study finds increasing incidence of cancer among adolescents and young adults

Radiation therapy before CART-BCMA appears to be a safe option for multiple myeloma patients

Study uses a statistical approach to reveal patterns of cancer incidence

Scientists identify genetic link to predict treatment response in patients with aggressive blood cancer

FDA approves first CAR T-cell therapy for patients with mantle cell lymphoma

AI Therapeutics announces start of Phase II clinical trial of potential COVID-19 treatment

First CAR T-cell therapy for mantle cell lymphoma receives FDA approval

Anaplastic large cell lymphoma: Defense mechanism against certain drugs promotes cancer growth

Breast cancer simulation models can guide screening recommendations for women

Tumor cell–based vaccine may prevent relapse of mantle cell lymphoma

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News